LumiraDx is transforming community-based healthcare by providing fast, accurate and comprehensive diagnostic information at the point of need, enabling better medical decisions that lead to improved outcomes at a lower cost.

The company’s innovative LumiraDx Platform is designed to perform a broad menu of tests including infectious disease, cardiovascular disease, diabetes, and coagulation disorders and deliver lab-comparable performance with results in less than 12 minutes.

Founded in 2014, LumiraDx is based in the UK with R&D and manufacturing sites across the US and Europe.  For more information, please visit www.lumiradx.com.